Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PROTEOMICS -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (336)	9/22/2001 1:01:50 PM
From: tuck	Read Replies (2) \| Respond to of 539

Wilder, I was surfing the X-Ray crytallography stuff again, in part to see if the Emerald BioStuctures folks (of MCLS) had tipped their hand at all regarding their techniques for resolving membrane-bound proteins. Didn't find much beyond topoisomerase stuff they made their names with, but found these related primers: "A Guide to Structure Prediction" bmm.icnet.uk "Protein Folding and Protein Structure Prediction" ismb2000.sdsc.edu Even the private companies SignalsMag identifies as leaders don't say much -- yet -- about their business models with respect to their discoveries. Yes, they intend to sell their targets or compounds they've IND'd. But for royalties or cash? I'd guess they'd go for single digit royalties if they take development as far as the IND stage. Emerald has had to settle for cash, which isn't helping MCLS as the outsourcing trend is apparently stalled by consolidation at big pharma, causing MCLS to downsize its laboratory operations. Apparently, the end results as yet do not have sufficiently proven utility to command a deals better than we've seen. Such as the Emerald/NBIX deal. Fun to watch, and to see how much of this is in San Diego, but hard to see how the serious money will be made. Wonder if they'll get munched before they make many deals. IPOing is tough; NetGenics finally withdrew its IPO recently. The VC haven't been getting much money by selling their BLUE H stocks at ridiculous prices. So I see that source drying up some and the cycle swinging back towards IPOs eventually. In the meantime: lean time. Cheers, Tuck